You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Tacrolimus (Prograf®, Advagraf®)

Find drug coverage information and forms for tacrolimus, by funding source. Coverage information includes Prograf (immediate release) and Advagraf (extended release).

What type of drug coverage does the patient have?

Private Insurance

  • Provide tacrolimus immediate release (IR) (Prograf) DIN 0216824 to patient to explore coverage through private insurer and if any special authorization forms are required.
  • Tacrolimus sustained release (SR) (Advagraf) may be covered by some private insurers.  Provide Tacrolimus SR sample DIN 02331667 if extended release formulation is preferred.

Ontario Drug Benefit (ODB) and OHIP+

  • Tacrolimus is not covered under limited use criteria for glomerulonephritis.
  • Tacrolimus IR (Prograf) will be considered for coverage under the Compassionate Review Policy (CRP) if intolerant to cyclosporine.
  • Complete Compassionate Review Policy (CRP) form. (See sidebar for form.)

Trillium Drug Program (TDP)

  • Enrol into TDP if not already enrolled.
  • Complete Compassionate Review Policy (CRP) form. (See sidebar for form.)

Federal Non-Insured Health Benefits (NIHB) Program

  • Prior approval required. Complete Exception Drugs Request Form provided by Drug Exception Centre.

Interim Federal Health Program (IFHP)

  • Medication coverage and duration of coverage varies depending on each individual’s situation.
  • Contact IFHP with tacrolimus DIN 0216824 for assessment of coverage.

No Medication Coverage

  • Option to pay cash for medication or enrol into TDP.
  • If enrolling in TDP, see TDP.

Disclaimer: The information contained herein (“Information”) is intended for informational purposes only, and no warranty as to its accuracy is provided or implied. The Information was collected from third party sources and is subject to change without notice. Cancer Care Ontario (CCO) makes no warranty that the Information is current. The Information is intended for use by healthcare professionals, subject to their clinical and/or professional judgment, to advise patients of drug funding options that may be available to them. Do not act or rely upon the Information without exercising your independent judgment or seeking the advice of a qualified professional. Anyone using the Information does so at his or er own risk. The drug funding options described herein are managed and funded by third parties, not by CCO. Please direct any inquiries to the applicable agency/entity who manages the drug funding option. CCO does not recommend or endorse the use of any drug or treatment method described herein.